跳至主要内容
临床试验/NCT06710067
NCT06710067招募中不适用

Observational Study of Urine Metabolites in the Diagnosis of Disease

Luventix, Inc.4 个研究点 分布在 1 个国家目标入组 1,250 人开始时间: 2024年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,250
试验地点
4
主要终点
Disease signal detection

研究概览

简要总结

The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases.

This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn's disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease.

The main questions it aims to answer are:

  1. Does the platform identify a disease signal within each disease cohort, compared to normal controls?
  2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years of age at time of enrollment.
  • Able and willing to provide a one-time urine sample and comply with all study procedures for the study.
  • Able to understand the study procedures, able to provide consent to participate in the study, and willing to authorize release of relevant protected health information by consenting to a HIPAA medical release form.

排除标准

  • Known to be pregnant.
  • A medical condition which, in the opinion of the Investigator and/or Sponsor, should preclude enrollment in the study.

结局指标

主要结局

Disease signal detection

时间窗: From date of enrollment to the end of sample analysis, up to 100 weeks

Disease signal detection quantification within each disease cohort, compared to normal controls.

Test performance measures

时间窗: From date of enrollment to the end of sample analysis, up to 100 weeks

Sensitivity and specificity/false-positive rate

次要结局

未报告次要终点

研究者

发起方
Luventix, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

Urine Metabolites in the Diagnosis of Disease | 临床试验